Vasc-Alert

What Vasc-Alert does

Vasc-Alert, LLC is a privately held healthcare technology company founded in 2002 and headquartered in West Lafayette, Indiana. The company was formed to commercialize a proprietary vascular access surveillance algorithm developed at Henry Ford Health Systems in Detroit, and received FDA approval in 2003. Vasc-Alert's core product is an FDA-cleared, non-invasive surveillance system that analyzes data already collected during routine hemodialysis treatments — including arterial pressure, venous pressure, mean arterial pressure, and blood flow rates — to calculate intra-access pressures and generate a validated 1-to-10 Access Risk Score (ARS) that predicts the likelihood of vascular access stenosis and thrombosis in patients with arteriovenous fistulas (AVF) and grafts (AVG). The platform delivers weekly and monthly surveillance reports, a prioritized Triage List Report, Financial Performance Analytics, a Patient Access Report Card for patient engagement, and EMR integration to embed outputs into existing dialysis center workflows.

The company operates a subscription-based business model, charging dialysis centers a nominal per-patient fee for ongoing surveillance, training, and support. Vasc-Alert targets outpatient dialysis centers and clinics as its primary customer segment, with nephrologists and vascular access coordinators as secondary clinical decision-support users. The technology has been adopted by hundreds of dialysis centers across the United States and the United Kingdom, and has analyzed more than 18 million dialysis treatments to date. Clinical validation includes peer-reviewed publications in the Journal of Vascular Access, Seminars in Dialysis, American Journal of Kidney Diseases, and Nephron, documenting outcomes such as 42.8% reductions in missed dialysis treatments, 55% reductions in thrombosis rates, and 79% AVF patency at 48 months versus a 44% benchmark. The company is led by Chairman & CEO Larry Day, with Douglas Curry as Vice-President and co-founder, supported by a small clinical and management team of 11-50 employees. In December 2023, Vasc-Alert filed an SEC Form D exempt securities offering for $1.5 million, marking its first disclosed external capital raise in over two decades of operation.

Name

Vasc-Alert

Legal name

Vasc-Alert, LLC

Website

https://vasc-alert.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

Vasc-Alert provides an FDA-approved, subscription-based vascular access surveillance system for hemodialysis patients, using a proprietary algorithm to generate a validated Access Risk Score from dialysis treatment data. The service is used by hundreds of dialysis centers across the US and UK.

Ownership category

akta.pro rank

Product category

Vascular Access Surveillance Software

NAICS

Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status) (HLAHAKAJ)

akta.pro secondary industries

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN) (HLALADAD)

Keywords

• Vascular access surveillance
• Hemodialysis risk scoring
• Dialysis access monitoring
• Predictive clinical analytics
• Renal care software

Headquarters

HQ city

West Lafayette

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Subscription Surveillance Service: As a subscription service, Vasc-Alert provides access surveillance on AV access patients including weekly and monthly reports, training, and ongoing support. Healthcare providers subscribe at a nominal cost per patient. The service generates recurring revenue from dialysis centers.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Vasc-Alert provides an FDA-approved, subscription-based vascular access surveillance service for hemodialysis patients. Its proprietary algorithm analyzes data already collected during each dialysis treatment (blood pump flow, arterial and venous pressures, mean arterial pressure) to calculate intra-access pressures and produce a 1-to-10 Access Risk Score predicting stenosis and thrombosis. Dialysis centers receive weekly and monthly reports, triage lists, financial performance analytics, and training to enable proactive clinical intervention.

Product overview

Vasc-Alert provides a unified vascular access surveillance platform for hemodialysis patients. The core product is the FDA-approved Vasc-Alert Surveillance System, which works in conjunction with the Access Risk Score (a 1–10 validated risk stratification tool) to identify patients at risk of vascular access stenosis and thrombosis. The platform delivers prioritized patient lists through the Triage List Report and provides patient-facing education via the Access Report Card. Weekly and monthly surveillance reports are delivered as part of a subscription service with training and ongoing support.

Differentiator

Problem solved

Functional benefit

Products and services

• Vasc-Alert Vascular Access Surveillance System FDA-approved, non-invasive vascular access surveillance service for hemodialysis patients with arteriovenous fistula (AVF) or arteriovenous graft (AVG). Uses data already collected during each dialysis treatment to calculate intra-access pressures, generate Access Risk Scores, and identify patients at risk of stenosis or thrombosis. Delivered as a subscription to dialysis centers and nephrology practices, with weekly and monthly reports, training, and ongoing support.
• Vasc-Alert Access Risk Score Validated 1-to-10 risk score that ranks hemodialysis patients by probability of vascular access complications. A score of 1 indicates low risk and 10 indicates high risk of stenosis or thrombosis; high scores (8-10) correlate with seven-fold higher odds of stenosis and trigger clinical referrals for access evaluation. Developed from analysis of 1.46 million hemodialysis treatments and validated on 298,620 treatments.

Quantifiable outcome

• 34% higher odds of stenosis per unit increase in Access Risk Score
• +8 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature5 records

Partnerships

One partnership is on record.

• Henry Ford Health SystemscoreStrategic or Co-development Partner · 1 January 2002Henry Ford Health Systems in Detroit developed the surveillance technology that was commercialized as Vasc-Alert. The company was formed in 2002 to commercialize this technology. Key personnel including Dr. Anatole Besarab and Dr. Lalathaksha Kumbar contributed to the technology development. Henry Ford Hospital served as the primary research site for validation studies.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Vivify Health: Remote patient monitoring and chronic care platform serving payers, providers, and employers. Comparable as an adjacent RPM/digital health company that overlaps with Vasc-Alert's continuous-monitoring model in chronic disease management.
• Outset Medical: Developer of the Tablo hemodialysis system for acute, chronic, and home dialysis. Operates in the same clinical workflow as Vasc-Alert and serves overlapping nephrology customers seeking technology-enabled, data-rich dialysis care.

Regional players

• U.S. Renal Care: Mid-sized US dialysis services provider that is a potential mid-market enterprise customer for Vasc-Alert's surveillance service. Comparable as a regional dialysis chain looking to deploy data-driven vascular access surveillance to reduce CVC rates.

Broad incumbents

• Fresenius Medical Care: The world's largest dialysis services and products company, operating thousands of dialysis centers and offering proprietary vascular access and care-management tools. It is simultaneously a potential large customer and a competitor with its own data-driven vascular access surveillance capabilities.
• AngioDynamics: Medical device company focused on vascular and oncology therapies, including dialysis vascular access products. Comparable to Vasc-Alert in serving the clinical pathway that addresses AV access stenosis and thrombosis in dialysis patients.
• DaVita: One of the two largest US dialysis providers, operating hundreds of outpatient clinics. DaVita's size and active focus on value-based nephrology make it both the largest potential enterprise customer and a competitor that could build in-house vascular access surveillance.
• Merit Medical Systems: Diversified medical device company with a significant vascular access portfolio (catheters, wires, sheaths, embolization products). Comparable because Merit competes for the same dialysis vascular access budgets that Vasc-Alert's surveillance reports help clinicians prioritize.
• Becton, Dickinson and Company (BD): Global medical technology company with a substantial vascular access and dialysis catheter business following the Bard acquisition. BD competes for the same dialysis vascular-access budgets and increasingly bundles digital and surveillance offerings into its product portfolio.
• NxStage Medical (Fresenius Medical Care): Now part of Fresenius Medical Care, NxStage developed home hemodialysis systems addressing the same ESRD patient population Vasc-Alert serves, shifting treatment modality away from in-center dialysis. The acquisition reflects dialysis incumbents' strategy to bundle devices, services, and monitoring.

Direct peers

• RenalSense: RenalSense develops the Clarity RMS critical care urinary output monitoring system for ICU and nephrology patients. It is the closest direct competitor to Vasc-Alert in continuous renal and fluid-status monitoring, with overlapping hospital and nephrology customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/vasc_alert
• LinkedInlinkedin.com/company/vasc-alert-llc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vasc-Alert